Group 1 - The core viewpoint of the news is that Quecheng Co., Ltd. has seen a significant increase in its stock price, rising by 5.64% to reach 21.55 CNY per share, with a total market capitalization of 8.962 billion CNY [1] - Quecheng Co., Ltd. is located in Wuxi City, Jiangsu Province, and specializes in the research, development, manufacturing, and sales of precipitated silica products, with 99.75% of its revenue coming from silica and 0.25% from other sources [1] Group 2 - From the perspective of fund holdings, Penghua Fund has a significant position in Quecheng Co., Ltd., with its Penghua New Materials Mixed Fund A (017667) holding 77,800 shares, unchanged from the previous period, representing 6.62% of the fund's net value [2] - The Penghua New Materials Mixed Fund A was established on March 28, 2023, with a current scale of 20.2866 million CNY and has achieved a year-to-date return of 12.36%, ranking 542 out of 8,847 in its category [2] - The fund manager, Wang Yunpeng, has been in position for 3 years and 117 days, with the fund's total assets amounting to 1.38 billion CNY, achieving a best return of 26.86% and a worst return of -13.19% during his tenure [3]

Core Viewpoint - Nar Holdings (002825.SZ) is restructuring to strengthen its core business by acquiring the remaining 33.5542% stake in Nantong Nar Material Technology Co., Ltd., increasing its ownership from 66.4458% to 100% [1][5] Group 1: Restructuring and Business Strategy - The acquisition aims to deepen Nar Holdings' strategic layout in the automotive protective film sector and enhance operational efficiency through resource integration [1][6] - The transaction will allow core employees to indirectly hold shares in the listed company, aligning their interests with the company's long-term goals [5][6] - Nar Holdings is also terminating a separate acquisition in the semiconductor sector to focus on its main business [2][7] Group 2: Financial Performance - For the first three quarters of 2025, Nar Holdings reported revenues of 1.468 billion yuan and a net profit of 144 million yuan, while Nantong Nar achieved revenues of 605 million yuan and a net profit of 66.66 million yuan, with a net profit margin that has doubled to 11.02% over the past two years [1][8] - Nantong Nar's financials show a steady increase in revenue and profitability, with net profit margins improving from 5.79% in 2023 to 11.02% in 2025 [7][8] Group 3: Asset and Liability Overview - As of September 2025, Nantong Nar's total assets were 458 million yuan, with total liabilities of 244 million yuan and equity of 214 million yuan [8] - Nar Holdings' financial performance includes a slight decline in net profit for the first three quarters of 2025, with a year-on-year decrease of 1.61% in non-recurring net profit [8]

深圳商报·读创客户端记者 李耿光 1月15日晚间，连续六年亏损、资产负债率突破104%的天晟新材（300169）公告控制权变更，并抛出定 增组合方案，公司股票将于2026年1月16日上午开市起复牌。 根据天晟新材公告，2026年1月14日，孙剑、吕泽伟与北京融晟鑫泰科技发展合伙企业（有限合伙） （以下简称"融晟鑫泰"）签署《股份转让协议》，约定融晟鑫泰以6.39元/股的价格协议受让两人合计 2048.95万股股份，协议转让完成后融晟鑫泰持股比例为6.29%。 同日，公司与北京融晟致瑞科技发展合伙企业（有限合伙）（以下简称"融晟致瑞"）签署《附条件生效 的股份认购协议》，融晟致瑞拟以现金方式认购公司本次发行的全部5000万股股票。本次发行完成后， 融晟致瑞持股比例为13.30%。 通过上述交易，融晟致瑞成为上市公司控股股东，融晟鑫泰为融晟致瑞的一致行动人，融晟致瑞及融晟 鑫泰的实际控制人尉立东成为上市公司实际控制人。 读创财经记者注意到，根据天眼查信息显示，融晟鑫泰与融晟致瑞均成立于2026年1月6日，距签署交易 协议仅8天，成立时间之短引发市场关注。 天晟新材同日披露了2026年度向特定对象发行股票预案。根据 ...

Core Viewpoint - Meierjian Biological Products (Shanghai) Co., Ltd. has been established with a registered capital of 5 million RMB, fully owned by Meierjian Biotechnology (Shanghai) Co., Ltd. [1] Company Information - The legal representative of Meierjian Biological Products (Shanghai) Co., Ltd. is Liu Bizuo [1] - The company is classified under the manufacturing industry, specifically in the chemical raw materials and chemical products manufacturing sector [1] - The registered address is located at No. 101, South District, 1st Floor, Building 1, 159 Cailun Road, China (Shanghai) Pilot Free Trade Zone [1] - The company type is a limited liability company (wholly foreign-owned enterprise) [1] - The business license allows for various activities including marine biological active substance extraction, purification, and synthesis technology research and development [1] Business Scope - The operational scope includes research and application of cell technology, manufacturing of specialized chemical products (excluding hazardous chemicals), medical research and experimental development, and development of human stem cell technology [1] - The company is also involved in human genetic diagnosis and treatment technology development, import and export of goods, and daily chemical product manufacturing [1] - Licensed projects include medical beauty services, life beauty services, and cosmetics production, which require approval from relevant authorities before commencement [1]

本报告期内，催化剂持续深化市场布局，稳固国内市场占有率，拓展海外业务实现增量，销量与销售收 入实现提升，效益显著；高硫石油焦制氢灰渣综合利用项目保持平稳高效运行，实现稳定经济效益。在 废塑料化学循环利用方面，20万吨/年混合废塑料资源化综合利用示范性项目顺利完成试生产，装置顺 利通过现场性能考核，充分验证了技术的成熟度与可靠性，打通从低值混合废塑料到高端聚烯烃产品的 全产业链，初步实现效益。公司各业务板块协同推进，本报告期利润较去年同期实现增长。 格隆汇1月15日丨惠城环保(300779.SZ)公布，预计2025年归属于上市公司股东的净利润5,500.00万元– 7,000.00万元，比上年同期增长29.11%-64.32%，扣除非经常性损益后的净利润4,200.00万元–5,700.00万 元，比上年同期增长40.35%-90.47%。 ...

证券日报网讯 1月15日，斯迪克发布公告称，公司第五届董事会第十六次会议审议通过《关于豁免公司 第五届董事会第十六次会议通知时限的议案》《关于与关联方共同投资暨关联交易的议案》。 （文章来源：证券日报） ...

Core Viewpoint - Silicon Treasure Technology has a strong portfolio of thermal conductive, potting, adhesive, and protective sealing materials, which are widely used in energy storage and power battery sectors [2] Group 1 - The company is actively expanding its business based on market and customer demands [2]

格隆汇1月15日丨天际股份(002759.SZ)公布，预计2025年归属于上市公司股东的净利润7,000万元– 10,500万元，同比扭亏为盈，扣除非经常性损益后的净利润6,000万元–9,000万元，同比扭亏为盈。由于 新能源汽车市场和储能市场需求快速增长，公司主要产品六氟磷酸锂在2025年第四季度销售价格上涨， 公司盈利能力恢复，第四季度实现利润并一举弥补前三季度亏损，实现全年扭亏为盈。同时公司秉持契 约精神，依约执行部分长协低价订单，一定程度上影响了公司盈利水平。公司子公司常熟新特化工有限 公司（以下简称"新特化工"）的主要产品次磷酸钠的市场行情亦在2025年第四季度好转，销售价格上 升，毛利率提高，结束了该主要产品亏损的局面，对公司整体业绩亦有重要贡献。虽然新特化工2025年 第四季度盈利能力有所恢复，但仍未完成2025年业绩目标，根据新特化工的业绩承诺及收购协议，新特 化工原股东应补偿公司相应差额，补偿金额计入非经常性损益。同时，公司从谨慎性原则出发，经初步 测试需计提部分商誉减值。 ...

Group 1 - The company, Jiu Ri New Materials, is a leading player in the photoinitiator sector and is the largest producer and supplier of photoinitiators globally [1] - The stock price in the secondary market is influenced by various factors including policy changes, economic environment, market sentiment, and investor behavior [1]

Reinstatement - Zhite New Materials and *ST Chengchang have completed their suspension investigations and their stocks have resumed trading [1][1] Share Buybacks and Equity Transfers - Hongli Zhihui's Mr. Li Guoping plans to transfer 5% of shares at a price of 5.93 CNY per share [2] - Luxshare Precision plans to repurchase company shares for between 1 billion to 2 billion CNY [2] - Defu Technology intends to repurchase shares for between 75 million to 150 million CNY, with a maximum repurchase price of 53.46 CNY per share [2] External Investments and Daily Operations - Hanyu Pharmaceutical has signed a sales order for GLP-1 raw materials worth 180 million CNY, which accounts for 30.50% of its audited revenue for 2024 [3] - Defu Technology plans to acquire a 26.32% stake in Amber New Materials for 509.5 million CNY [4] - Changchun High-tech has received a one-time payment of 70 million USD from Yarrow for the exclusive licensing agreement related to the GenSci098 injection project [4] - Zhongchuang Zhiling plans to issue convertible bonds to raise no more than 4.35 billion CNY for various high-end manufacturing projects [4] - Triangle Tire intends to invest 3.219 billion CNY to establish a new company in Cambodia for the production of 7 million high-performance radial tires annually [4] - Zhejiang Zhongtuo's subsidiary Hunan Zhongtuo has been selected as a restructuring investor for Jiangsu Delong Nickel Industry and 30 other companies [4] Performance Changes - Tianji Co. expects a net profit of 70 million to 105 million CNY in 2025, with a recovery in profitability due to rising sales prices of lithium hexafluorophosphate [5] - SAIC Group anticipates a net profit of 9 billion to 11 billion CNY in 2025, representing a year-on-year increase of 438% to 558% [6] - Shengnuo Bio expects a net profit of 152 million to 190 million CNY in 2025, a year-on-year increase of 204.42% to 280.53% [6] - Zhenghai Magnetic Materials forecasts a net profit of 310 million to 380 million CNY in 2025, with a year-on-year increase of 235.72% to 311.52% [6] - Sanmei Co. expects a net profit of 1.99 billion to 2.15 billion CNY in 2025, a year-on-year increase of 155.66% to 176.11% [6] - Tongxing Technology anticipates a net profit of 68 million to 88 million CNY in 2025, a year-on-year increase of 74.2% to 125.44% [7] - Luoyang Molybdenum expects a net profit of 20 billion to 20.8 billion CNY in 2025, a year-on-year increase of 47.80% to 53.71% [8] - Nawei Technology forecasts a net profit of 12.8 million to 14.5 million CNY in 2025, a year-on-year increase of 54.51% to 75.03% [9]